|By PR Newswire||
|February 3, 2014 06:00 AM EST||
LOS ANGELES, Feb. 3, 2014 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) today announced that Andrew Gengos, Chief Executive Officer, will present a corporate overview and business update at the 16th Annual BIO CEO & Investor Conference at 1:30 pm ET on Monday, February 10, 2014, at the Waldorf Astoria Hotel in New York City.
To access the live audio webcast of the BioCentury NewsMakers presentation, please log on through a link located in the Investors section of ImmunoCellular's website at www.imuc.com, under the Events & Presentations tab. A replay of the webcast will be available one hour after the conclusion of the live event.
About ImmunoCellular Therapeutics, Ltd.
ImmunoCellular Therapeutics, Ltd. is a Los Angeles area-based clinical-stage company that is developing immune-based therapies for the treatment of brain and other cancers. ImmunoCellular has concluded a phase II trial of its lead product candidate, ICT-107, a dendritic cell-based vaccine targeting multiple tumor-associated antigens for glioblastoma. ImmunoCellular's pipeline also includes ICT-121, a dendritic cell vaccine targeting CD133, and ICT-140, a dendritic cell vaccine targeting ovarian cancer antigens and cancer stem cells. To learn more about ImmunoCellular, please visit www.imuc.com.
For ImmunoCellular Therapeutics, Ltd.
SOURCE ImmunoCellular Therapeutics, Ltd.
Jul. 7, 2015 02:00 AM EDT Reads: 1,201
Jul. 7, 2015 01:15 AM EDT Reads: 833
Jul. 6, 2015 11:00 PM EDT Reads: 1,914
Jul. 6, 2015 07:45 PM EDT Reads: 1,611
Jul. 6, 2015 07:45 PM EDT Reads: 1,896
Jul. 6, 2015 07:00 PM EDT Reads: 1,116
Jul. 6, 2015 06:15 PM EDT Reads: 1,960
Jul. 6, 2015 05:30 PM EDT Reads: 1,141
Jul. 6, 2015 05:00 PM EDT Reads: 2,161
Jul. 6, 2015 05:00 PM EDT Reads: 1,973
Jul. 6, 2015 04:30 PM EDT Reads: 681
Jul. 6, 2015 04:15 PM EDT Reads: 1,573
Jul. 6, 2015 03:45 PM EDT Reads: 1,765
Jul. 6, 2015 03:00 PM EDT Reads: 1,807
DevOps tends to focus on the relationship between Dev and Ops, putting an emphasis on the ops and application infrastructure. But that’s changing with microservices architectures. In her session at DevOps Summit, Lori MacVittie, Evangelist for F5 Networks, will focus on how microservices are changing the underlying architectures needed to scale, secure and deliver applications based on highly distributed (micro) services and why that means an expansion into “the network” for DevOps.
Jul. 6, 2015 03:00 PM EDT Reads: 3,047